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Abstract
Background: The breadth of the clinical spectrum underlying Pelizaeus-Merzbacher disease and spastic paraplegia
type 2 is due to the extensive allelic heterogeneity in the X-linked PLP1 gene encoding myelin proteolipid protein
(PLP). PLP1 mutations range from gene duplications of variable size found in 60-70% of patients to intragenic
lesions present in 15-20% of patients.
Methods: Forty-eight male patients from 38 unrelated families with a PLP1-related disorder were studied. All DNA
samples were screened for PLP1 gene duplications using real-time PCR. PLP1 gene sequencing analysis was
performed on patients negative for the duplication. The mutational status of all 14 potential carrier mothers of the
familial PLP1 gene mutation was determined as well as 15/24 potential carrier mothers of the PLP1 duplication.
Results and Conclusions: PLP1 gene duplications were identified in 24 of the unrelated patients whereas a
variety of intragenic PLP1 mutations were found in the remaining 14 patients. Of the 14 different intragenic
lesions, 11 were novel; these included one nonsense and 7 missense mutations, a 657-bp deletion, a
microdeletion and a microduplication. The functional significance of the novel PLP1 missense mutations, all
occurring at evolutionarily conserved residues, was analysed by the MutPred tool whereas their potential effect
on splicing was ascertained using the Skippy algorithm and a neural network. Although MutPred predicted that
all 7 novel missense mutations would be likely to be deleterious, in silico analysis indicated that four of them (p.
Leu146Val, p.Leu159Pro, p.Thr230Ile, p.Ala247Asp) might cause exon skipping by altering exonic splicing
elements. These predictions were then investigated in vitro for both p.Leu146Val and p.Thr230Ile by means of
RNA or minigene studies and were subsequently confirmed in the case of p.Leu146Val. Peripheral neuropathy
was noted in four patients harbouring intragenic mutations that altered RNA processing, but was absent from
all PLP1-duplication patients. Unprecedentedly, family studies revealed the de novo occurrence of the PLP1
duplication at a frequency of 20%.
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Mutations in the PLP1 gene are responsible for a wide
range of X-linked white matter disorders, collectively
termed PLP1-related disorders, which together represent
a continuum of neurological features, that characterize
conditions ranging from Pelizaeus-Merzbacher disease
(PMD, MIM# 312080) with severe CNS involvement to
the milder spastic paraplegia type 2 (SPG2, MIM#
312920) [1-3]. The PMD phenotype, which includes
both the severe ‘connatal’ and ‘classic’ forms of the dis-
ease, typically manifests with nystagmus, hypotonia, cog-
nitive impairment, severe spasticity and ataxia. In the
‘connatal’ form, nystagmus is present at birth and may
be associated with stridor and hypotonia. Ambulation
and speech are usually not achieved. The classical form
of PMD is usually characterized by the onset in early
infancy of nystagmus, initial hypotonia leading to spasti-
city, ataxia, variable extrapyramidal involvement and
cognitive impairment. Supported ambulation may be
achieved, although it may eventually be lost during fol-
low-up. The so called “PLP1 null syndrome” is charac-
terized by the occurrence of peripheral neuropathy that
is typically absent in the other PLP1-related disorders.
SPG2 may be either ‘complicated’ or ‘pure’ according to
the presence or absence of symptoms other than spastic
gait and autonomic dysfunction [3]. Brain magnetic
resonance imaging (MRI) reveals a diffuse hypomyelinat-
ing leukoencephalopathy in children with the PMD phe-
notype, whereas in SPG2, either patchy abnormalities on
T2-weighted images or a more diffuse leukoencephalo-
pathy may occur [3].
The proteolipid protein gene (PLP1; MIM# 300401)
contains seven exons and spans ~17 kb of chromosome
Xq22.2 [4,5]. PLP1 encodes both the 277 amino acid pro-
teolipid protein 1 (PLP) and its 242 amino acid isoform,
DM20, which is derived from the use of a developmen-
tally regulated internal splice donor site within PLP1
exon 3 [6,7]. The in vivo functional significance of the
two distinct isoforms has not yet been fully elucidated
[8,9]. PLP and DM20 are however known to be differen-
tially expressed both during development and within dif-
ferent regions of the nervous system [10]. DM20,
ubiquitously present both in the myelinating Schwann
cells and in non-myelinating cells, is the predominant
product during embryonic stages of development [11,12],
but is overtaken postnatally by PLP which is abundantly
expressed in oligodendrocytes and accounts for 17% of
the total myelin protein [13]. The amino acid sequence
of PLP has been highly conserved during mammalian
evolution, with human, mouse and rat PLP sequences
being completely homologous to each other [14].
The remarkable variety of mutations in the PLP1 gene
that lead to the arrest of myelination can be grouped
into two main categories: PLP1 gene duplications of
variable size (60-70%) and intragenic sequence variants
(15-20%) [2,3,15,16]. The deletion of the entire PLP1
gene has been reported in barely 2% of patients [17,18]
whilst position effect rearrangements have been reported
in a very small number of individuals with both PMD
and SPG2 [19,20]. Finally, triplication and quintuplica-
tion of the PLP1 gene also occur, albeit very rarely [2,3].
To date, more than 160 different disease-causing PLP1
mutations have been reported [see the Human Gene
Mutation Database [http://www.hgmd.org] [21] and the
Leiden Locus-Specific Database (http://grenada.lumc.nl/
LOVD2/MR/home.php)].
To date, our clinical and diagnostic center has provided
a definitive diagnosis for 47 unrelated patients with PLP1-
related disorders. We have previously reported the study
of 9 unrelated patients, 8 of whom were males carrying
the PLP1 gene duplication [22,23] whilst the remaining
female harboured a very large duplication of Xq with ran-
dom X inactivation that led to brain hypomyelination
together with multiple congenital anomalies [24]. Here we
report the molecular characterization of the PLP1 defect
in a further 38 families with PLP1-related disorders, com-
prising a total of 43 patients. Molecular findings from this
patient series have revealed that 24 of the unrelated
patients possessed PLP1 gene duplications whereas the
remaining 14 patients harboured mostly novel PLP1 cod-
ing sequence or splicing-relevant mutations.
Methods
Patients
The present patient series comprised a total of 43 male
patients from 38 unrelated families with a diagnosis of a
PLP1-related disorder. The diagnosis was predicated
upon clinical evaluation and was supported by MRI stu-
dies performed in all patients except one. The main
clinical and neuroradiological findings of these patients
are summarized in Table 1.
Ethical aspects
Following ethical guidelines, all cell and nucleic acid
samples were obtained for analysis and storage with the
patients’ (and/or a family member’s) written informed
consent. The consent was sought using a form approved
by the local Ethics Committee.
Cell culture
Fibroblast and lymphoblast cells were cultured accord-
ing to standard procedures. The cell lines were cultured
and maintained in RPMI medium (EuroClone, Gibco,
Paisley, UK) containing 15% FCS and penicillin/strepto-
mycin, in a humidified atmosphere containing 5% CO2
at 37°C.
Oli-neu (murine oligodendrocyte precursor) cells
(kindly provided by Dr. J. Trotter, University of Mainz,
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Page 2 of 13Table 1 Clinical, neuroradiological and molecular findings of the patients
Fam/
Pt
ID
Age
at
onset
Age at
last
evaluation
Clinical
symptoms
at onset
Developmental
delay/
Mental
retardation
Neurological
findings
Peripheral
neuropathy
Clinical
severity
score#
Brain
MRI
findings
Molecular findings
Genotype Nature of
mutation
♣
1 Birth 8 y Nystagmus
Muscular
hypotonia
Severe MR Axial
hypotonia
Limb spasticity
Pyramidal
signs
+ 0 Hypo
(Supra/
Infra)
c.453G>T (p.
Lys151Asn)♠
Inherited
2 Birth 5 m Nystagmus
Stridor
+ Spastic
tetraparesis
Absent 0 Hypo c.552C>G
(p.Cys184Trp)
Inherited
3 Birth 4 y Nystagmus
Muscular
hypotonia
+ Muscular
hypotonia
NT 0 Hypo
(Supra/
Infra)
c.689C>T
(p.Thr230Ile)
Inherited
4 Birth 12 y Nystagmus
Muscular
hypotonia
Severe MR Muscular
hypotonia
Pyramidal
signs
Absent 1 Hypo
(Supra/
Infra)
c.89C>A
(p.Ala30Glu)
Inherited
5 2 m 2 y Nystagmus + Spastic
tetraparesis
Absent 1 Hypo
(Supra/
Infra)
c.505T>C
(p.Cys169Arg)
Inherited
6 Birth 3 y Nystagmus
Muscular
hypotonia
Mild MR Muscular
hypotonia
Pyramidal
signs
Absent* 1 Hypo c.554_564del11
♠ (p.
Gln185LeufsX15)
Inherited
7 Birth 18 y Nystagmus
Muscular
hypotonia
Severe MR Muscular
hypotonia
Pyramidal
signs
Absent 1 Hypo c.634T>C Inherited
Birth 2 y Nystagmus
Muscular
hypotonia
Mild MR Muscular
hypotonia
Pyramidal
signs
Absent 1 Hypo (p.Trp212Arg)
8 3 m 4 y Nystagmus
Muscular
hypotonia
Mild MR Spastic
tetraparesis
+ 2 Hypo
(Supra/
Infra)
c.205C>T
(p.Gln69X)♠
Inherited
9 8 m 9 y Nystagmus
Developmental
delay
Mild MR Spastic
tetraparesis
+ 3 Hypo c.1-329_c.1_c.4
+324del657♠
Inherited
10 4 m 14 y Nystagmus
Muscular
hypotonia
+ Spastic
tetraparesis
+ 3 Hypo
(Supra/
Infra)
c.134_140dup7
(p.Ile47IlefsX4)♠
Inherited
11 6 m 30 y Nystagmus - Limb spasticity
Poor tendon
reflexes
NT 4 NT c.436C>G (p.
Leu146Val)♠
Inherited
12 Birth 11 m Nystagmus
Stridor
+ Muscular
hypotonia
NT ♦ Hypo c.83G>T
(p.Gly28Val)
Inherited
13 Birth 11 m Nystagmus Mild MR Muscular
hypotonia
Absent ♦ Hypo
(Supra/
Infra)
c.476T>C
(p.Leu159Pro)
De novo
14 1 m 3 m Nystagmus
Muscular
hypotonia
+ Muscular
hypotonia
NT ♦ Hypo c.740C>A
(p.Ala247Asp)
Inherited
15 Birth 5 y Nystagmus
Muscular
hypotonia
Severe MR Muscular
hypotonia
Pyramidal
signs
Absent 0 Hypo
(Supra/
Infra)
PLP1dup NA
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16 Birth 18 m Nystagmus
Muscular
hypotonia
Stridor
Mild MR Muscular
hypotonia
Absent 0 Hypo
(Supra/
Infra)
PLP1dup De novo
17 1 m 17 y Nystagmus Mild MR Muscular
hypotonia
Absent 1 Hypo
(Supra/
Infra)
PLP1dup NA
18 3 m 10 y Nystagmus
Muscular
hypotonia
+ Muscular
hypotonia
Pyramidal
signs
Dystonia
Ataxia
Absent 1 Hypo PLP1dup Inherited
2 m 11 y Nystagmus
Muscular
hypotonia
Moderate MR Spastic
tetraparesis
Dystonia
Absent 1 Hypo
19 1 m 2 y Nystagmus Moderate MR Muscular
hypotonia
Pyramidal
signs
Dystonia
Absent 1 Hypo
(Supra/
Infra)
PLP1dup Inherited
20 1 m 4 y Nystagmus Mild MR Muscular
hypotonia
Pyramidal
signs
Absent 2 Hypo PLP1dup Inherited
21 2 m 4 y Nystagmus + Muscular
hypotonia
Absent 2 Hypo PLP1dup NA
22 2 m 4 m Nystagmus
Muscular
hypotonia
Mild MR Muscular
hypotonia
Absent 2 Hypo PLP1dup NA
23 4 m 2 y Nystagmus Mild MR Muscular
hypotonia
Absent 2 Hypo PLP1dup Inherited
24 Birth 22 y Nystagmus Severe MR Spastic
tetraparesis
Dystonia
Absent 2 Hypo PLP1dup Inherited
25 8 m 2 y Nystagmus
Developmental
delay
+ Spastic
tetraparesis
Absent 2 Hypo PLP1dup Inherited
26 1 m 4 y Nystagmus Severe MR Pyramidal
signs
Dystonia
Absent 2 Hypo PLP1dup Inherited
27 5 m 2 y Nystagmus Severe MR Muscular
hypotonia
Absent 2 Hypo PLP1dup De novo
15 d 5 y Nystagmus
Seizures
Moderate MR Spastic
tetraparesis
Dystonia
Absent 2 Hypo
28 1 m 8 y Nystagmus + Pyramidal
signs
Dystonia
Absent 2 Hypo PLP1dup Inherited
4 m 29 y Nystagmus
Seizures
+ Pyramidal
signs
Dystonia
Absent 3 Hypo
29 1 y 25 y Nystagmus
Developmental
delay
Severe MR Spastic
tetraparesis
Absent 3 Hypo PLP1dup Inherited
1 y 23 y Nystagmus
Developmental
delay
Severe MR Spastic
tetraparesis
Absent 3 Hypo
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horse serum [25].
Molecular analysis
All DNA samples were initially screened for the presence of
the PLP1 gene duplication using real-time PCR. In a subse-
quent step, sequencing analysis was performed on every
patient who was found to be negative with respect to the
gene duplication. Where necessary, further investigations
on RNA samples were carried out whenever possible.
Genomic DNA was extracted from peripheral blood leuko-
cytes and/or cultured cell lines using standard methods or
suitable kits [QIAmp DNA blood mini kit (Qiagen Inc.,
Valencia, CA, USA) or the Nucleon BACC3 kit for blood
and cell cultures (Amersham Biosciences, Bucks, UK)].
Total RNA was extracted from patient fibroblasts
using an RNeasy mini plus kit (Qiagen, Valencia, CA,
USA) and reverse transcribed by means of an Advantage
RT-for-PCR kit (BD Biosciences Clontech, Mountain
View, CA, USA).
PLP1 gene dosage determination by real-time PCR
DNA samples from the patients were assessed for PLP1
gene dosage by real-time PCR using amplicon PLP1gen,
located in exon 3 of the PLP1 gene, and amplicon GAP-
gen, located in exon 7 of the glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) gene which was used as
a reference sequence [26].
PLP1 gene dosage was determined by real-time PCR
amplification from genomic DNA. Amplicons defined by
two primers and a TaqMan probe were designed for the
real-time PCR runs using the Primer Express 1.5 soft-
ware (Applied Biosystems, Foster City, CA, USA)
according to previously reported requirements [26]. The
real-time PCR experiments were performed using the
Applied Biosystems 7500 Real-Time PCR System with
TaqMan chemistry as previously described [26]. The
standard curve method, with amplification of the target
and reference sequences in separate tubes, was
employed (User Bulletin #2. Relative quantitation of
gene expression; http://www.appliedbiosystems.com/).
Samples were run in quadruplicate whereas standards
were run in duplicate. All TaqMan probes used were
labelled with FAM as the reporter fluorophore at their
5’-end and with BHQ1 as the quencher at their 3’-end.
Primers and probes were purchased by TIB Molbiol
(Genoa, Italy).
Table 1 Clinical, neuroradiological and molecular findings of the patients (Continued)
30 3 m 5 y Nystagmus Mild MR Muscular
hypotonia
Pyramidal
signs
Absent 3 Hypo
(Supra/
Infra)
PLP1dup Inherited
31 Birth 3 m Nystagmus
Muscular
hypotonia
Mild MR Muscular
hypotonia
Absent 3 Hypo PLP1dup NA
32 2 m 6 y Nystagmus Moderate MR Pyramidal
signs
Ataxia
Absent 3 Hypo PLP1dup Inherited
33 6 y 30 y Nystagmus
Learning
difficulties
Behavioural
problems
Moderate MR Limb spasticity
Ataxia
Absent 4 Hypo PLP1dup NA
34 3 m 11 m Nystagmus
Muscular
hypotonia
+ Muscular
hypotonia
Pyramidal
signs
Absent ♦ Hypo
(Supra/
Infra)
PLP1dup Inherited
35 1 m 7 m Nystagmus + Muscular
hypotonia
Absent ♦ Hypo PLP1dup NA
36 3 m 11 m Nystagmus
Muscular
hypotonia
+ Muscular
hypotonia
Dystonia
Absent ♦ Hypo PLP1dup NA
37 1 m 11m Nystagmus + Muscular
hypotonia
Absent ♦ Hypo PLP1dup De novo
38 3 m 8 m Nystagmus
Muscular
hypotonia
+ Muscular
hypotonia
Absent ♦ Hypo
(Supra/
Infra)
PLP1dup NA
Legend: Fam = Family; Pt = Patient; d = day(s) m = month(s); y = year(s); NT = not tested; * indicates peripheral neuropathy present in the symptomatic mother;
MR = mental retardation; MRI = magnetic resonance imaging; Hypo = hypomyelination; Supra = supratentorial; Infra = infratentorial; # according to Cailloux et al.
[35]; ♦indicates score not assessable in patients below 12 months of age; NA = not available; ♠flags mutations predicted to alter RNA processing; ♣indicates
data based on molecular findings in the mother’s DNA samples
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All PLP1 gene exons and exon-intron boundaries were
PCR amplified to yield 5 amplicons using 5 sets of pri-
mers designed by reference to the PLP1 genomic
sequence (GenBank-EMBL Accession No.
NC_000023.10). Reverse transcript-PCR (RT-PCR) was
performed using sets of primers designed by reference
to the PLP1 mRNA sequence (GenBank accession No.
NM_000533.3) Primers and PCR reaction conditions are
given in Additional file 1, Table S1a. All amplicons were
purified and directly sequenced using an ABI 377 DNA
automated sequencer with dye terminator cycle sequen-
cing kits (Applied Biosystems, Foster City, CA, USA).
Putative mutations were confirmed by sequencing
duplicate PCR products or by digesting PCR products
with a specific restriction endonuclease whose recogni-
tion site was consequently altered. If the mutation
neither created nor destroyed a restriction site, amplifi-
cation was carried out using PCR-mediated site-directed
mutagenesis that served to introduce a new restriction
enzyme cleavage site [27]. The possibility that the novel
mutations were polymorphisms was excluded by deter-
mining that none of 50 female healthy control subjects
(100 alleles) carried any of these alterations. Further, by
definition, none of the novel variants had ever been
reported before (as either a disease-causing mutation or
a polymorphism) in any previous study.
Bioinformatic analysis of PLP1 variants
Missense variants in the PLP1 gene were analysed by
means of a computational model, MutPred [28,29].
MutPred was designed to model the effect of observed
changes in structural and functional sites within a protein
between wild-type and mutant protein sequences.
MutPred can also be used to generate hypotheses as to the
underlying molecular mechanism(s) responsible for dis-
ease pathogenesis for any given mutation. The effects of
coding region variants upon splicing [splice site disruption,
cryptic splice site activation and exon skipping, as a conse-
quence either of the loss of an exonic splicing enhancer
(ESE) and/or the gain of an exonic splicing silencer (ESS)]
were ascertained using Skippy [30] and a neural network
for splice site prediction [31]. The NI-ESR hexamers [32]
(979 ESEs and 496 ESSs) formed the basis of the ESE and
ESS motifs used in this analysis, as this set had previously
been identified as providing the strongest signal for identi-
fying exon skipping variants [30].
Mutation c.436C>G (p.Leu146Val): minigene splicing
construct and quantitative real-time RT-PCR-based
evaluation of PLP1 and DM20 transcript content
A PCR product containing portions of exon/intron 2,
exon/intron 3 and exon 4 was obtained from a healthy
control using primers PP2F and PP4R that introduced
ClaIa n dEcoRI sites (Additional file 1, Table S1b). The
product was cleaved with ClaIa n dEcoRI and cloned
into a similarly cleaved pcDNA3.1/V5-His-TOPO/LacZ
vector (Invitrogen, San Diego, CA). A recombinant in-
frame LacZ-PLP1-LacZ minigene, containing the geno-
mic region between exons 2 and 4 of the PLP1 gene,
was then obtained. The cloned fragment was sequenced,
thereby confirming its identity to the PLP1 gene refer-
ence sequence. Subsequently, the c.436C>G (p.Leu146-
Val) mutation was introduced into the vector using the
QuikChange II Site-Directed Mutagenesis Kit (Strata-
gene Agilent, Santa Clara, California, USA) according to
the manufacturer’s instructions. Wild-type and mutant
plasmid constructs were transfected into murine oligo-
dendroglial Oli-neu cells using the lipofectamine 2000
Transfection Reagent (Invitrogen, San Diego, CA)
according to the manufacturer’s instructions. Trans-
fected cells were harvested 72 hrs after transfection, and
RNA was extracted using an RNeasy Plus Mini kit (Qia-
gen, Valencia, CA, USA) and reverse transcribed using
the Advantage RT-for-PCR kit (BD Biosciences Clon-
tech, Mountain View, CA, USA). Reverse transcription
was performed using a LacZ reverse primer (LACT2R)
in order to avoid retrotranscription of endogenous Plp1
gene transcripts from the Oli-neu cells. RT-PCR was
performed using the primers reported in Additional
file 1, Table S1b.
To evaluate PLP and DM20 transcript content quanti-
tatively in cells transfected with wild-type and mutant
constructs, a real-time PCR analysis was performed, as
previously described, using a DM20 transcript-specific
amplicon (D2), a PLP transcript-specific amplicon (P2),
both encompassing exons 3 and 4, and a (DM20+PLP)
transcript-specific amplicon (P23B) encompassing exons
2 and 3 (Additional file 1, Table S1c). While amplicons
D2 and P2 were used as targets, amplicon P23B was
used as a reference. Using this experimental approach,
we were able to derive the DM20/(DM20+PLP)a n d
PLP/(DM20+PLP) ratios for cells transfected with wild-
type and mutant constructs. Wild-type and mutant
cDNAs were run in quadruplicate, each well containing
the cDNA obtained from 10 ng RNA. A plasmid con-
taining the DM20 cDNA was used to generate the stan-
dard curve for the D2 amplicon whilst a plasmid
containing the PLP cDNA was used to generate the
standard curves for the P2 and the P23B amplicons,
respectively. Standards were r u ni nd u p l i c a t e .S t a n d a r d
wells contained 10-2, 10-3, 10-4, 10-5, 10-6, 10-7 ng/μl
plasmid DNA.
Mutation nomenclature
All mutations are described according to the recom-
mended nomenclature [33,34]. Nucleotide numbering
was derived from the human PLP1 cDNA sequence
(GenBank-EMBL Accession No. NM_000533.3) ascrib-
ing the A of the first ATG translational initiation codon
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derived for the human PLP protein (GenBank-EMBL
Accession No. NP_000524.3).
Results and Discussion
In this study we report the molecular genetic analysis of
43 patients with PLP1-related disorders from 38 unre-
lated families. The clinical, neuroradiological and mole-
cular findings obtained in relation to the 43 patients are
summarized in Table 1.
Clinical aspects
As reported in Table 1, 15 patients (pts) (from 14
families) were found to possess PLP1 mutations
whereas the remaining 28 patients (from 24 families)
harboured a PLP1 duplication. Age at onset of clinical
symptoms ranged from birth to 1 year old, with the
exception of one patient (pt #33) who was reported as
having nystagmus, learning difficulties and behavioural
problems in childhood. The age at last evaluation ran-
ged from 3 months to 30 years (Table 1). Nystagmus,
either isolated or associated with other symptoms, was
the presenting symptom in all patients. The other pre-
senting symptoms in the 43 patients were: seizures (2/
43), stridor (3/43), developmental delay (4/43) and
muscular hypotonia (18/43). Developmental delay and
mental retardation (ranging from mild to severe) were
reported during follow-up in all patients except for pt
#11. Neurological findings revealed abnormal muscular
tone with prevailingly axial hypotonia or diffuse mus-
cular hypotonia in the youngest subjects associated
with pyramidal signs in 11/43. Increased muscle tone,
either limb spasticity (3 pts) or tetraparesis (11 pts),
was evident in older patients. Dystonia was present in
9 patients (in association with pyramidal signs in 8/9)
and ataxia in three patients. Peripheral neuropathy
(confirmed by nerve conduction velocity studies) was
present in four subjects with PLP1 mutations but was
absent in all patients harbouring a PLP1 duplication. A
reduced amplitude of the compound muscle action
potential, consistent with an axonal neuropathy, was
identified in two subjects (pts #1 and #9), whereas a
mixed axonal and demyelinating process was diagnosed
in two further patients (pts #8 and #10).
Clinical severity, assessed according to the score pro-
posed by Cailloux et al. [35], ranged from 0 to 4 on the
basis of the maximal level of motor acquisition. Three
out of five patients with the lowest score (i.e. no pos-
tural achievement) belonged to the PLP1 mutation
group, whereas the remaining two patients harboured
PLP1 duplications. Nine patients, having achieved head
control, had a score of 1: of these, five were in the PLP1
mutation group whereas four were in the PLP1 duplica-
tion group. Eleven patients, 10 of whom carried a PLP1
duplication, were able to sit without assistance, thereby
obtaining a score of 2. Of the 8 patients who acquired
the ability to walk with support (viz. score 3), two were
in the PLP1 mutation group whereas six were in the
PLP1 duplication group. Finally, only two patients, one
with a PLP1 mutation and the other with a PLP1 dupli-
cation, acquired the ability to walk without support,
thereby obtaining a score of 4. Brain MRI indicated
hypomyelination in all 42 patients who had undergone
brain MRI. In 14/17 patients, from whom more detailed
neuroradiological data were available, infratentorial mye-
lin deficiency was present in addition to the supraten-
torial hypomyelination that was evident in all patients.
Molecular studies
The laboratory diagnostic protocol included an initial
screening, by real-time PCR, of all DNA samples for the
presence of the PLP1 gene duplication. In the next step,
patients negative for the gene duplication underwent
PLP1 sequencing analysis. Analysis of the present
patient series revealed a PLP1 gene duplication in 24 of
the unrelated patients whereas a variety of intragenic
PLP1 mutations was found to underlie disease patho-
genesis in the remaining 14 unrelated patients (Table 1).
Table 2 reports the characteristics of the 14 different
genomic lesions identified in these patients as a result of
sequencing the exons and exon-intron boundaries of the
PLP1 gene. Figure 1 depicts the distribution of the cod-
ing sequence mutations in relation to the proposed
model of the tetra-span proteolipid proteins, PLP and
DM20 [36,37].
Eleven of the mutations were novel and included (i) 7
missense mutations (p.Gly28Val, p.Ala30Glu, p.Leu146-
Val, p.Leu159Pro, p.Cys184Trp, p.Thr230Ile, p.
Ala247Asp) and one nonsense mutation (p.Gln69X); (ii)
a large deletion (c.1-329_c.1_c.4+324del657) involving
the removal of 657-bp from the untranslated, exonic
and intronic regions surrounding exon 1; (iii) a microde-
letion (c.554_564del11) which results in a frameshift (p.
Gln185LeufsX15) that is predicted to introduce a pre-
mature stop codon 15 residues downstream; and (iv) a
microduplication in exon 2 (c.134_140dup7) which
would also be predicted to lead to a frameshift (p.Ile47I-
lefsX4) with premature truncation of the protein four
amino acids downstream.
The question of the pathological authenticity of the
novel PLP1 sequence alterations detected was addressed
by (i) searching dbSNP (http://www.ncbi.nlm.nih.gov/
SNP) for their annotation and excluding their presence,
(ii) screening 50 healthy female control subjects (100
alleles) for each alteration and determining that none
carried any of these alterations, (iii) analysing the evolu-
tionary conservation of the amino acid residues affected,
(iv) employing the MutPred program [28,29] to assess
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Page 7 of 13each missense mutation, and (v) using Skippy [30] and a
neural network for splice site prediction [31] to explore
the potential for mutational consequences for splicing.
Analysis of the evolutionary conservation of amino acid
residues affected by missense mutations
Support for the pathological relevance of the missense
mutations identified in the present study, came from
the analysis of the extent of evolutionary conservation
of the mutated residues in 9 orthologous (vertebrate)
PLP proteins. Computational analysis (http://www.
ensembl.org/) revealed that all missense mutations
occurred at evolutionarily conserved amino acid resi-
dues. Moreover, seven of the novel mutations affected
amino acid residues (namely Gly28, Ala30, Leu159,
Cys184, Trp212, Thr230 and Ala247) that were invar-
iant even when zebrafish PLP was considered (Addi-
tional file 2, Table S2).
MutPred analysis
In an attempt to assess the functional relevance or
otherwise of the novel PLP1 missense mutations identi-
fied, we employed the in silico analysis tool, MutPred
[28,29]. MutPred predicted that all 7 novel missense
mutations listed in Table 2 would be deleterious
(MutPred general score > 65) whilst confident in silico
hypotheses for the underlying mechanism of pathogen-
esis were generated for two of them. Thus, protein sec-
ondary structure was predicted to be altered by the
missense mutations p.Gly28Val (P = 0.025) and p.
Leu159Pro (Helix to Sheet; P = 0.027); the latter repla-
cement (p.Leu159Pro) was also predicted to give rise to
a gain of glycosylation at p.Thr160 (P = 0.034).
The effect of the coding region variants upon splicing
[including splice site disruption, cryptic splice site acti-
vation and exon skipping via loss of exonic splicing
enhancers (ESE), and/or gain of exonic splicing silencers
(ESS)] was ascertained using Skippy [30] and a neural
network for splice site prediction [31]. Whereas this lat-
ter algorithm predicted that only p.Lys151Asn would
abolish the 5’ splice site, as already reported by Hobson
et al. [38], the results of the Skippy analysis (Table 2)
indicated that four other missense mutations (p.Leu146-
Val, p.Leu159Pro, p.Thr230Ile, p.Ala247Asp) could
potentially cause exon skipping by altering exonic spli-
cing elements (ESR). In all four instances, the exon pre-
dicted to be skipped would be the same as that
harbouring the mutation (Table 2, Location). The dra-
matic copy number changes of ESE or ESS motifs for p.
Leu146Val and p.Thr230Ile further identified these
novel missense mutations as being high confidence
‘exon skipping’ candidates suitable for further in vitro
analysis. Indeed, c.436C>G (p.Leu146Val) appears to
lead to a net gain of 5 exon splicing silencer (ESS)
motifs, whilst c.689C>T (p.Thr230Ile) results in the net
loss of 5 exon splicing enhancers (ESE) as well as the
gain of an ESS motif. The potential impact of both p.
Leu146Val and p.Thr230Ile on PLP1 mRNA processing
was therefore investigated by means of RNA or mini-
gene studies.
Deduced consequences of PLP1 mutations for mRNA
processing
The postulated effect of mutations c.436C>G (p.Leu146-
Val) and c.689C>T (p.Thr230Ile) on PLP1 mRNA pro-
cessing was explored in vitro as follows:
Mutation c.436C>G (p.Leu146Val)
Since no RNA sample was available from pt #11, the
functional consequences of the mutation c.436C>G (p.
Leu146Val) were assessed using a recombinant mini-
gene construct containing a PLP1 exon 2-exon 4 frag-
ment, cloned into an expression vector. Oli-neu cells
were then transfected with the wild-type (c.436C) and
mutant (c.436G) versions of the construct, and RNA
samples extracted. To avoid the synthesis of endogen-
ous murine Oli-neu Plp1 transcripts, first strand cDNA
was reverse transcribed using a minigene-specific pri-
mer. RT-PCR products from the mutant construct
(c.436G) revealed only the presence of the DM20-speci-
fic transcript (the PLP-specific transcript being totally
a b s e n t )w h e nc o m p a r e dw i t ht h ew i l d - t y p ec o n s t r u c t
(c.436C) (Figure 2a). To further corroborate these data,
we evaluated the [DM20]/[DM20+PLP]a n d[ PLP]/
[DM20+PLP] ratios in cells transfected with the wild-
type and mutant constructs, by real-time PCR quantifi-
cation using [DM20]- [PLP]- and [DM20+PLP]-specific
amplicons. As expected, whereas the [DM20]/[DM20
+PLP] ratio displayed by the mutant construct was
0.998 (compared to 0.707 for the wild-type control), the
[PLP]/[DM20+PLP] ratio associated with the mutant
construct was 0.019 vs 0.192 for the wild-type construct
(Figure 2b). These findings indicate that the mutation
c.436C>G (p.Leu146Val) abolished PLP isoform-specific
splicing, thereby confirming our in silico predictions.
Thus, only the transcript corresponding to the DM20
isoform was found in association with the p.Leu146Val
PLP1 mutation.
Mutation c.689C>T (p.Thr230Ile)
Based on the in silico prediction (loss of 5 ESE motifs
and gain of 1 ESS motif), an alteration of the splicing
phenotype was expected for this missense mutation.
RT-PCR analysis of PLP1 RNA isolated from the fibro-
blasts of pt #3 (using the PLPF-PLP1R primer set
reported in Additional file 1, Table S1c), revealed
instead the presence only of normally-sized 1040-bp
and 915-bp products of the PLP and DM20 isoforms,
respectively, both of which harboured the missense
mutation.
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Page 8 of 13Table 2 Characteristics of PLP1 gene mutations identified in 14 unrelated patients and MutPred analysis of the
missense mutations
Location cDNA
mutation*
Mutation Effect MutPred analysis of missense mutations Refer
ence
Probability
of
deleterious
mutation
No. of
ESE
binding
sites
loses
No. of
ESS
binding
sites
gained
Skippy
Log Odds
Ratio
(LOR)
Total
Splice site disruption
prediction
5’UTR-
Ex 1-Intr
1
c.1-329_c.1_c.4
+324del657
r.? . . . . Present
study
c.134_140dup7 p.Ile47IlefsX4 . . . . Present
study
Exon 2 c.83G>T p.Gly28Val 0.80 SS Loss of
loop
(P = 0.0252)
0 1 0.052 Present
study
c.89C>A p.Ala30Glu 0.84 0 0 -5.884 Present
study
c.205C>T p.Gln69X . 0 2 1.290 Present
study
c.436C>G p.Leu146Val 0.67 0 5 0.356 Present
study
Exon 3 c.453G>T p.Lys151Asn 0.63 0 0 -1.284 [predicted to abolish
5’SS with Neural
Network] already
reported in the cited ref
Hobson
et al.
[38]
c.476T>C p.Leu159Pro 0.87 SS Helix >
Sheet
(P = 0.0266),
Gain of
glycosylation
at T160
(P = 0.0342)
6 0 1.360 Present
study
Exon 4 c.505T>C p.Cys169Arg 0.91 4 0 1.360 Mimault
et al.
[48]
c.552C>G p.Cys184Trp 0.88 2 0 -0.929 Present
study
c.554_564del11 p.
Gln185LeufsX15
. Present
study
Exon 5 c.634T>C p.Trp212Arg 0.79 Loss of
catalytic
residue at
L210
(P = 0.0114),
Gain of
methylation
at W212
(P = 0.0245)
0 0 -1.284 Cailloux
et al.
[35]
c.689C>T p.Thr230Ile 0.68 5 1 2.696 Present
study
Exon 6 c.740C>A p.Ala247Asp 0.88 1 2 2.006 Present
study
* Nucleotide numbers are derived from cDNA PLP1 sequence (GenBank-EMBL accession no. NM_000533.3) taking as nucleotide +1 the A of the first ATG
translation initiation codon; Bold type denotes novel mutation; Ex = exon; Intr = Intron; ESE = exonic splicing enhancers; ESS = exonic splicing silencers; Skippy
Log Odds Ratio (LOR) score is the output from the Skippy tool [30], the Skippy LOR score represents the likelihood that the combination of ESR changes
consequent to a substitution are associated with exon skipping. The higher the Skippy LOR score, the more likely the combination of ESR changes will be
associated with an exon skipping event. The prediction of splice site disruption was evaluated using a neural network. The column ‘Location’ refers to the exon
within which the mutation occurs and also the exon that could potentially be skipped due to ESE loss and/or ESS gain.
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Page 9 of 13Characterization of the gross deletion (c.1-329_c.1_c.4
+324del657)
The genomic breakpoints of the large genomic deletion
were found to overlap 4 nucleotides of exon 1 (including
the start codon ATG), the flanking upstream 329-bp
untranslated region (5’UTR) and the downstream 324-bp
intronic regions, respectively. We then evaluated its conse-
quences for RNA processing by means of quantitative real-
time PCR. These experiments, performed on RNA
extracted from the fibroblasts of pt #9, indicated that the
PLP transcript isoform was completely absent, whereas the
DM20 transcript isoform was present at a reduced level,
~50% as compared to healthy controls (data not shown).
The recombinational mechanism underlying the gross
deletion was then explored. Since no significant homolo-
gies were detected at the deletion breakpoints, we infer
that non-homologous end-joining (NHEJ) may have
been responsible for this deletion [39,40]. The underly-
i n gm e c h a n i s mm a ya l s oh a v ei n v o l v e ds e q u e n c ee l e -
ments present at the 5’ breakpoint [i.e. an A-rich
sequence and a polypurine tract (both 17 bp long)] and
3’ breakpoint [a tract highly homologous to the translin
site consensus sequence], previously reported as being
over-represented at translocation breakpoints [41].
Genotype-phenotype correlations
A remarkable number of different PLP1 mutations have
been reported as being responsible for disease pathogen-
esis in PLP1-related disorders. It has generally been
observed that patients with PLP1 gene duplications dis-
play a range of clinical severity, independent of the
extent of the duplication [22,42]. This variation in clini-
cal severity is also evident in our patient series; indeed,
the clinical severity scores varied between 0 and 4 in dif-
ferent patients.
Peripheral neuropathy, never reported in patients with
PLP1 gene duplications, has been frequently found to be
associated with intragenic PLP1 mutations that either
abrogate PLP1 expression (null alleles), affect the PLP-
specific region or alter certain PLP1 splice sites [43,44].
In accordance with these general observations, periph-
eral neuropathy was absent in all 24 families with a
PLP1 duplication (Table 1). Interestingly, only those
patients (#1, #8, #9, #10) who harboured PLP1 muta-
tions that were predicted to result in the absence of the
PLP isoform, exhibited peripheral neuropathy [as con-
firmed by nerve conduction velocity studies (NCVs)].
Although NCVs in another patient (#6) who harboured
a null allele were within the normal range for his age (2
years), his carrier mother exhibited spastic paraplegia
and peripheral neuropathy with severe slowing of nerve
conduction velocity.
Analysing the clinical severity score of each patient in
the PLP1 mutation group in relation to the type of
mutation, the most severe phenotype (score = 0) (Table
1 pts #1, #2 and #3) was found to be associated with (i)
the p.Lys151Asn mutation, which occurred at the
Figure 1 Distribution of PLP1 gene mutations identified in our
series of patients with PLP1-related disorders in relation to the
proposed model* of the tetra-span proteolipid proteins, PLP
and DM20. With respect to the missense mutations reported here,
the amino acid residues affected by novel mutations are shown in
purple, whereas residues harbouring previously reported mutations
are given in green. The four predicted transmembrane domains
(TMD1-4) are depicted, the first and last amino acids being
indicated for each TMD. The PLP1-specific region (which is absent
from DM20) is denoted by a dotted line. The locations of the two
disulfide bridges (Cys184-Cys228 and Cys201-Cys220) within loop B
(LB) are marked “S–S”. The double arrow indicates the relative
placement of the exon-exon (Ex) junctions superimposed upon the
PLP1 protein. *model according to Popot et al, [36] and Weimbs
and Stoffel [37]
Figure 2 Mutation c.436C>G (p.Leu146Val). a) RT-PCR performed
with the minigene-specific 31GF/LACT2R primers (Additional file 1,
Table S1b) on cDNA transfected into Oli-neu cells. Whereas the
expected PLP1 and DM20 products were present in cells transfected
with the wild-type construct (WT), only the DM20 product was
present in cells transfected with the patient mutant construct (Pt).
No product was present in untransfected cells (U) or in the negative
control lacking DNA (B). FX174 DNA HaeIII digest used as a marker
(M). b) Real-time PCR quantification using [DM20]- [PLP]- and [DM20
+PLP]-specific amplicons confirmed the altered ratio of DM20/(DM20
+PLP) (blue bars) and PLP/(DM20+PLP) (red bars) in the patient
carrying the mutation Leu146Val as compared to the healthy
control.
Grossi et al. Orphanet Journal of Rare Diseases 2011, 6:40
http://www.ojrd.com/content/6/1/40
Page 10 of 13alternative 5’ splice donor site of the PLP and DM20
isoforms, and which altered levels of both the PLP- and
DM20-encoding RNAs [38]; (ii) the novel substitution
(p.Cys184Trp), that replaced a cysteine known to be
involved in disulfide bridge formation (Cys184-Cys228)
(Figure 1) with a tryptophan (Trp), and which is likely
to destabilize the folded protein and induce the UPR
(unfolded protein response) pathway leading to apopto-
sis [45]. Recently, the Cys184Arg substitution has been
reported as a cause of the ‘classic’ form of PMD [46]
thereby supporting our contention that any defect invol-
ving the disulfide bridge (Cys184-Cys228) would
strongly impair correct PLP folding; (iii) the substitution
of an amino acid residue (p.Thr203Ile) that is common
to both the PLP and DM20 isoforms and is evolutiona-
rily invariant even when zebrafish PLP is considered
(Additional file 2, Table S2).
The least severe phenotype (clinical severity score = 4)
was noted in patient #11 who harboured the lesion
c.436C>G (p.Leu146Val); in vitro studies confirmed that
this mutation results in altered PLP1 RNA processing,
leading to the production of the DM20 isoform in the
absence of the PLP isoform (Figure 2). The findings out-
lined above are therefore in accord with previous observa-
t i o n so fp a t i e n t sw i t hPLP1-related disorders in whom a
relatively mild syndrome is associated with mutations that
affect the PLP isoform but not the DM20 isoform [2,3,16].
Family studies
The mutation analysis was extended wherever possible
to all female family members. So far, although de novo
mutations have been reported in several instances of
PLP1 point mutations, de novo mutation appears at the
very least to be much rarer (and is perhaps unprece-
dented) in the case of PLP1 duplications (see Hodes et
al. [47], and Mimault et al. [48], for discussion of this
still contentious issue). Mimault et al. [48] analysed the
maternal mutation status of 56 families; whereas in 22
families with PLP1 gene mutations, 32% of mothers
were found not to be carriers of the mutation con-
cerned, these authors found that only three (9%) of 34
mothers of PLP1 duplication patients (analyzed by a
multiplex endpoint PCR-based approach) were not car-
riers. On the basis of a statistical analysis which revealed
a significant male duplication imbalance, these authors
suggested that the PLP1 duplications could have arisen
in the grandpaternal germline.
In our own patient series, we analyzed all 14 obligate
carrier mothers of the familial PLP1 gene mutation and
15/24 obligate carrier mothers of the PLP1 duplication.
In contrast to the previously reported results, the PLP1
mutations were all found to be maternally inherited
with the sole exception of pt #13, in whom the missense
mutation appears to have occurred de novo (7%).
However, the PLP1 duplication was found to have
occurred de novo in 3 of the 15 mothers analyzed (20%)
(Table 1). The proportion of PLP1 duplications occur-
ring de novo in our series is significantly higher than the
9% reported by Mimault et al. [48] The limited number
of cases analyzed here (15 mothers) notwithstanding,
the de novo occurrence of the PLP1 gene duplication at
a frequency of 20% is quite unprecedented. If these
novel and unexpected findings are confirmed on a larger
number of patients, the previously postulated high pre-
valence of a grandpaternal origin for the PLP1 duplica-
tion will have to be re-evaluated. The relatively high
frequency of de novo PLP1 duplication reported here
would certainly concur with recent findings indicating a
rather higher de novo mutation rate for CNVs than for
point mutations [49,50]. It may well be that the discre-
pancy between our own data and those previously
reported is due to the greatly improved analytical meth-
ods currently in use for the identification of the PLP1
duplication.
Although a high rate of de novo duplication was docu-
mented in our study, gonadal mosaicism could not be
formally excluded in the patient’sm o t h e r sw h ow e r e
found to be negative with respect to a specific mutation.
Therefore, in clinical practice, prenatal testing is recom-
mended for those couples potentially at risk. Female car-
riers of PLP1-related disorders are generally normal
neurologically, but may manifest mild to moderate signs
of late onset disease [3]. It is however known that those
mutant PLP1 alleles that are responsible for hemizygous
males being affected with comparatively mild neurologi-
cal disease symptoms, may also give rise to neurological
manifestations in female heterozygotes [51]. In addition,
owing to favourably skewed X inactivation in heterozy-
gous females with a PLP1 duplication, the risk of a car-
rier female being clinically affected is lowest in the case
of a PLP1 duplication and highest in the presence of a
PLP1 null allele [52]. None of the 15 mothers studied
here who were heterozygous for the PLP1 duplication
were clinically affected. On the other hand, of the 14
mothers who were carriers of an intragenic PLP1 muta-
tion, neurological impairment (spastic paraplegia and
peripheral neuropathy) was reported only in the mother
(Table 1, Fam #6) who harboured a putative null allele
(p.Gln185LeufsX15).
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